Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus

Journal of Rheumatology

Volumn 26, Issue 11, 1999, Pages 2363-2368

  Rahman, Proton ^a   Urowitz, Murray B ^a,c   Gladman, Dafna D ^a   Bruce, Ian N ^a   Genest Jr , Jacques ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Coronary artery disease; Risk factors; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; CYTOTOXIC AGENT; PREDNISONE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ADULT; AGED; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032748103     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality of systemic lupus erythematosus. Am J Med 1976;60:221-5.
2. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985; 55:87-98.
3. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989;68:141-50.
4. Manzi S, Meilahn EN, Rairie JE, et al. Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
5. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med 1975; 58:243-64.
6. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995;22:1259-64.
7. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for CAD in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
8. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987;14 Suppl 13:223-6.
9. Petri M, Spence D, Bone LR, Hochberg MC. CAD risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventive practices. Medicine 1992;71:291-302.
10. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood pressure in adults. Adult treatment panel II. JAMA 1993;269:3015-23.
12. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;28:630-40.
13. Genest JJ, McNamara JR, Ordovas JM, et al. Effect of hospitalization on plasma lipoprotein cholesterol and apolipoproteins A-1, B and Lp(a). Am J Cardiol 1990;65:677-9.
14. Abrahamowicz M, Grodzicky T, Senecal JL, et al. Myocardial infarction and stroke in SLE: markedly increased incidence after controlling for risk factors [abstract]. Lupus 1998;7 Supp 1:69.
15. Hodis HN, Quismorio FP, Wickham E, et al. The lipid lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993;20:661-5.
16. Petri M, Rubenoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
17. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lipoprotein(a) as a risk factor for coronary artery disease and cerebral infarction. Atherosclerosis 1986;260:1655-60.
18. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992;2:457-66.
19. Ginsberg HN. Lipoprotein metabolism and its relationship to atherosclerosis. Med Clin N Am 1995;79:951-71.
20. Ames PRJ. Medical perspective: antiphospholipid antibodies, thrombosis, and atherosclerosis in systemic lupus erythematosus: a unifying "membrane stress syndrome" hypothesis. Lupus 1994;3:371-7.
21. Neufeld HN, Goldbourt U. Coronary heart disease: genetic aspects. Circulation 1983;67:943-54.
22. Berg K. Genetics of coronary heart disease. Prog Med Genet 1983;5:35-90.
23. Colditz GA, Rimm EB, Giovannucci E, et al. A prospective study of parental history of myocardial infarction and CAD in men. Am J Cardiol 1991;67:933-8.
24. Kannel WB, Wilson PWF. An update on coronary risk factors. Med Clin North Am 1995;79:951-71.
25. Wilson PWF, Evans JC. Coronary artery disease prediction. Am J Hypertension 1993;6:309S-13S.
26. Bruce IN, Gladman DD, Urowitz MB. Detection and control of risk factors for atheroma in patients with SLE. Clin Exp Rheumatol 1998;16:435-40.
27. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal analysis. Am J Med 1994:96:254-9.
28. MacDonald S, Joffres MR, Stachenko S, et al. Multiple cardiovascular disease risk factors in Canadian adults. Can Med Assoc J 1992;146:2021-9.
29. McNicoll S, Latour Y, Rondeau C, et al. Cardiovascular risk profiles and lipoprotein profile in French Canadians with premature CAD. Impact of the National Cholesterol Education Program II. Can J Cardiol 1995:11:109-16.
30. Genest J Jr, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:1185-9.